Nasdaq

Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of ...
Nasdaq

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $42.6 Million for February 2022

TAMPA, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
Seeking Alpha

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

BRISBANE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of ...
Business Insider

Pacira BioSciences Reports Full-Year 2019 Preliminary Revenue of $421.0 Million

PARSIPPANY, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary unaudited ...